Antivascular endothelial growth factor (VEGF) therapy is used to treat a wide variety of malignancies, in the front-line setting and beyond.4 Sorafenib (Nexavar; Bayer HealthCare Pharmaceuticals Inc) was the first VEGF tyrosine kinase inhibitor (TKI), approved in 2005 for the treatment of advanced renal cell carcinoma.5 After this approval, anti-VEGF therapies began expanding into other areas in cancer care in a similar manner to PD-1/PD-L1 inhibitors.
Results from clinical trials studying the combination of PD-1/PD-L1 and VEGF inhibitors for the treatment of various malignancies began to be published and FDA approvals followed shortly thereafter. The first approved combination of antiPD-1/PD-L1 and anti-VEGF therapy, atezolizumab (Tecentriq; Genentech, Inc) and bevacizumab (Avastin; Genentech, Inc), in December 2018, was for the treatment of metastatic nonsquamous nonsmall cell lung cancer.6 The same combination was also approved for the treatment of hepatocellular carcinoma in May 2020.7
Pharmacology
AntiPD-1/PD-L1 monoclonal antibodies, also termed checkpoint inhibitors, are referred to generally as immunotherapy, and more recently as immuno-oncology. These agents exert anticancer activity by binding PD-1 or PD-L1 that is present on the surface of tumor cells and CD8-positive T cells, thus blocking the interaction. When PD-1 and PD-L1 bind normally, it causes downregulation of the immune system. Therefore, the prevention of these inhibitory signals, in effect, stimulates the immune system to target tumors. Whether the agent is an antiPD-1 or antiPD-L1 monoclonal antibody, the effect is the same.8 At present, FDA-approved antiPD-1 monoclonal antibodies include pembrolizumab, nivolumab, and cemiplimab (Libtayo; Regeneron Pharmaceuticals, Inc), and antiPD-L1 monoclonal antibodies include atezolizumab, avelumab (Bavencio; EMD Serono), and durvalumab (Imfinzi; AstraZeneca Pharmaceuticals LP).9
Anti-VEGF therapies are subdivided into 3 subclasses: orally administered TKIs, intravenous (IV) monoclonal antibodies, and an IV recombinant fusion protein. The TKIs sorafenib, sunitinib (Sutent; Pfizer), pazopanib (Votrient; Novartis Pharmaceuticals Corporation), lenvatinib (Lenvima; Eisai Inc), regorafenib (Stivarga; Bayer HealthCare Pharmaceuticals Inc), cabozantinib (Cabometyx; Exelixis, Inc), axitinib (Inlyta; Pfizer), and vandetanib (Caprelsa; AstraZeneca Pharmaceuticals LP) are multikinase inhibitors, as they bind and antagonize several types of receptor tyrosine kinases in addition to VEGF.10 PDGFRs, FGFRs, and KIT inhibitors also lend their use in diverse malignancies according to driver mutations in these receptors.10
The anti-VEGF monoclonal antibodies are inherently more specific than the TKIs; those on the market include bevacizumab and ramucirumab (Cyramza; Eli Lilly and Company).9 Bevacizumab binds to circulating VEGF type A, preventing it from binding a VEGF receptor. Ramucirumab, on the other hand, binds to the extracellular portion of the VEGF receptor, thereby blocking the binding of VEGF and causing a similar effect.10
Lastly, ziv-aflibercept (Zaltrap; Sanofi-Aventis US LLC) is a recombinant fusion protein with limited indications; it acts as a decoy receptor for VEGF type A and B.11
Combination Therapy
Previous research results have elucidated the role of tumor-produced VEGF in solid tumor angiogenesis in addition to immune system downregulation, which allows for tumor growth and immune system escape.4,12 Although the antiangiogenetic effects of VEGF inhibitors are partly responsible for the disease responses observed, the inhibition of immune system downregulation caused by tumor-produced VEGF is another pharmacodynamic mechanism that can be exploited to achieve better outcomes.4
Considering the anti-immunosuppressive effects of VEGF inhibitors, it stands to reason that synergy is seen when VEGF inhibitors are combined with PD-1/PD-L1 inhibitors.13 Therefore, investigators and drug manufacturers are exploring this combination in several malignancies in which PD-1/PD-L1 inhibitors and VEGF inhibitors currently play a role in treatment, exclusive of one another.
The fundamental approach taken in combination chemotherapy is such that the individual agents in a regimen have differing dose-limiting toxicities and mechanisms. In this manner, multiple agents can be combined with differing adverse effects so that toxicities are not additive. Rather, toxicities that are separated over a range of types can be individually managed while the additive or even synergistic efficacy of all the agents is maintained.14
The strategy of combination therapy began with cytotoxic chemotherapy regimens and has since evolved into targeted and monoclonal antibody therapies, with PD-1/PD-L1 and VEGF inhibitors representing a relatively novel pairing in cancer care. The Table shows a summary of PD-1/PD-L1 and VEGF inhibitor combinations currently approved by the FDA.
Patient Eligibility
AntiPD-1/PD-L1 monoclonal antibodies are often approved with minimum requirements of PD-L1 expression upon tumor staining, which is measured in combined positivity score (CPS) or tumor proportion score (TPS). Tumors with microsatellite instabilityhigh (MSI-H) status or mismatch repair deficiency (dMMR) may be another condition often attached to the indication for antiPD-1/PD-L1 monoclonal antibodies. Notably, only 1 indication for a PD-1/PD-L1 and VEGF inhibitor combination has 1 of these conditions: patients with advanced endometrial cancer must not have MSI-H or dMMR disease status to qualify for treatment with pembrolizumab and lenvatinib.15 No other PD-1/PD-L1 and VEGF inhibitor combinations have these requirements included with their FDA approval, affording more opportunities for patients to benefit from therapy.
Dozens of clinical trials evaluating PD-1/PD-L1 and VEGF inhibitor combinations are listed on ClinicalTrials.gov, and most are actively recruiting. They are assessing combinations along with the addition of chemotherapy and other targeted therapies. Given the number of trials in process and the results previously seen, it is likely that more approvals of this combination are on the horizon.
Conclusions
PD-1/PD-L1 inhibitors continue to change the cancer treatment landscape, and the relatively new combination with VEGF inhibitors represents a promising option for patients with various malignancies. Most likely, the trend of combined PD-1/PD-L1 and VEGF inhibition therapy will keep expanding into areas in which PD-1/PD-L1 and VEGF inhibitors are already being used.
VINCENT J CASCONE, PHARMD, BCOP, is a clinical oncology pharmacist at the University of Kansas Health System in Kansas City.
REFERENCES
Read the original post:
Use of PD-1/PD-L1 and VEGF Inhibition Combination Is Expanding - Pharmacy Times
- Technion team discovers important adaptive strategy of the microbiome, impacting immune system - The Jerusalem Post - April 16th, 2024
- Targeting aging and age-related diseases with vaccines - Nature.com - April 16th, 2024
- Single cell analysis unveils B cell-dominated immune subtypes in HNSCC for enhanced prognostic and therapeutic ... - Nature.com - April 16th, 2024
- After the Smoke Clears: Scars on the Immune System - The Scientist - April 16th, 2024
- Exercise and the Immune System: What's the Latest Research? - Technology Networks - April 16th, 2024
- Analysis of immune cell infiltration characteristics in severe acute pancreatitis through integrated bioinformatics ... - Nature.com - April 16th, 2024
- Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original ... - Nature.com - April 16th, 2024
- Harnessing the power of the body's own cells to defeat cancer - Press Publications Inc. - April 16th, 2024
- Best Life: Immunotherapy targets brain cancer - Action News 5 - April 16th, 2024
- Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review | Cell Death ... - Nature.com - April 16th, 2024
- New insights on B cells: Researchers explore building better antibodies and curbing autoimmune diseases - Medical Xpress - April 16th, 2024
- Immune cells' intense reaction to the coronavirus may lead to pneumonia - Science News Magazine - April 16th, 2024
- The telltale traces long Covid leaves in the blood - healthcare-in-europe.com - April 16th, 2024
- Overview of the Immune System - The Merck Manuals - March 18th, 2024
- SUNDAY Unraveling The Gut-Brain Connection: How Infant Gut Bacteria Shape Immune Resilience | TheHealthSit - TheHealthSite - March 18th, 2024
- Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics | npj Systems Biology and ... - Nature.com - March 18th, 2024
- Study unlocks the mystery of neonatal neutropenia in newborns - News-Medical.Net - March 18th, 2024
- Vertebral Subluxation and Systems Biology: An Integrative Review Exploring the Salutogenic Influence of Chiropractic ... - Cureus - March 18th, 2024
- A new strategy to attack aggressive brain cancer shrank tumors in two early tests - ABC News - March 18th, 2024
- Turning on the Bat Signal - The Scientist - March 18th, 2024
- Power Foods That Can Support Your Immune System - Videos from The Weather Channel - The Weather Channel - March 18th, 2024
- Report: Aggressive brain tumors respond to new, immune-focused therapy - UPI News - March 18th, 2024
- Designer immune-cell therapy could shrink deadly brain tumors, early trials show - Livescience.com - March 18th, 2024
- 20.2: Introduction to the Immune System - Biology LibreTexts - February 27th, 2024
- Can one shot of yoghurt really boost your immunity and gut health? - Daily Mail - February 27th, 2024
- New cancer therapy approved by FDA supercharges bodys immune system - The Washington Post - February 27th, 2024
- How bubonic plague rewired the human immune system - BBC.com - February 27th, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Participate in Our Study for $100; Open Slots This Week - University of Arkansas Newswire - February 27th, 2024
- Sexual dimorphism during integrative endocrine and immune responses to ionizing radiation in mice | Scientific Reports - Nature.com - February 27th, 2024
- Comprehensive pan-cancer analysis identifies the RNA-binding protein LRPPRC as a novel prognostic and immune ... - ScienceDirect.com - February 27th, 2024
- YOUR HEALTH: The HAMR fights cancer - WAFB - February 27th, 2024
- Cycles of a diet that mimics fasting can reduce signs of immune system aging, as well as insulin resistance and liver fat - News-Medical.Net - February 27th, 2024
- How the powerhouse of the cell could be cancers Achilles heel - Freethink - February 27th, 2024
- Food is medicine: The science behind zinc and other supplements for immune health - Healio - February 27th, 2024
- Unleashing Our Immune Response to Quash Cancer - Medscape - February 27th, 2024
- Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 ... - Nature.com - February 27th, 2024
- Converging and evolving immuno-genomic routes toward immune escape in breast cancer - Nature.com - February 27th, 2024
- Sanjula Jain Urges a Comprehensive Approach in Address Alarming Rise in Cancer Cases Among Younger Populations - Managed Healthcare Executive - February 27th, 2024
- Cystic fibrosis breakthrough points to zinc as infection buster - New Atlas - February 27th, 2024
- Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIVworkshop ... - Nature.com - February 27th, 2024
- Is the 100-year old TB vaccine a new weapon against Alzheimers? - The Guardian - February 27th, 2024
- Immune system in the blood of Alzheimer's patients found to be epigenetically altered - News-Medical.Net - February 10th, 2024
- What impact does exercise have on your immune system? And how to stay well while cycling - BikeRadar - February 10th, 2024
- Had COVID recently? Here's what to know about how long immunity lasts, long COVID, and more - AAMC - February 10th, 2024
- Noor Momin harnesses the immune system to treat heart disease | Penn Today - Penn Today - February 10th, 2024
- Research reveals a process tumors use to induce immune suppressor cells and evade immunotherapy - Medical Xpress - February 10th, 2024
- Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure - Nature.com - February 10th, 2024
- Preventing severe allergic reactions with nanoparticles - National Institutes of Health (NIH) (.gov) - February 10th, 2024
- Sugary handshakes are how cells talk to each other understanding these name tags can clarify how the immune ... - The Conversation Indonesia - February 10th, 2024
- Scientists have identified an immune cell that can cause allergies - EL PAS USA - February 10th, 2024
- Sickle cell and the importance of the immune system - Punch Newspapers - February 10th, 2024
- Which cancers can be treated with immune checkpoint inhibitors? - MD Anderson Cancer Center - February 10th, 2024
- How does waste leave the brain? Washington University School of Medicine in St. Louis - Washington University School of Medicine in St. Louis - February 10th, 2024
- Healthy Kids: Give your immune system a boost to stay healthy this winter - nbc16.com - February 10th, 2024
- The impact of prior exposure to hypoglycaemia on the inflammatory response to a subsequent hypoglycaemic episode ... - Cardiovascular Diabetology - February 10th, 2024
- Impact of Chronic Stress on Immune System and Depression | Health News - Medriva - February 10th, 2024
- I tried 'swamp soup,' the viral recipe that promises to boost your immune system - Yahoo News - February 10th, 2024
- Understanding Immune Checkpoint Inhibition Therapy: Challenges and Strategies - Medriva - February 10th, 2024
- One Simple Change May Dramatically Boost The Effect of COVID-19 Vaccines - ScienceAlert - February 10th, 2024
- The gut virome is associated with stress-induced changes in behaviour and immune responses in mice - Nature.com - February 10th, 2024
- Cancer vaccines are in the works to fight BRCA-linked gene mutations - The Philadelphia Inquirer - February 10th, 2024
- What are the organs of the immune system? - InformedHealth.org - NCBI ... - January 17th, 2024
- Novel insights into the immune response to bacterial T cell superantigens - Nature.com - January 17th, 2024
- FDA signs off on Takeda's HyQvia as maintenance therapy for CIDP - FiercePharma - January 17th, 2024
- CBDs Pobezinsky and Pobezinskaya Use Flow Cytometry to Determine How Tumor Cells Outwit the Bodys Immune ... - UMass News and Media Relations - January 17th, 2024
- Boosting. What To Do. - Science Based Medicine - January 17th, 2024
- Axelia Oncology takes its TLR2/6 agonist into the clinic to harness the innate immune system - BioWorld Online - January 17th, 2024
- Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to ... - Nature.com - January 17th, 2024
- Opinion | Thanks to mRNA, Future Drugs Will Be Easier and Faster to Make - Mississippi Free Press - January 17th, 2024
- Elon research team models the COVID immune response, one equation at a time - Today at Elon - January 17th, 2024
- Are plant-based meals good for your immune system? 4 things to know about improving your health this week. - Yahoo Life - January 17th, 2024
- Scientists Find Key To Potential Breast Cancer Prevention, Treatment | Newsroom - UNC Health and UNC School of Medicine - January 17th, 2024
- What if every germ hit you at the exact same time? An immunologist explains - The Conversation - January 17th, 2024
- Why Don't We Have a Staph Vaccine? - Healthnews.com - January 17th, 2024
- Best ways to improve your immune system - The Business Standard - January 17th, 2024
- Stanford University researchers think future pandemics could be prevented with universal vaccines - KGO-TV - January 17th, 2024
- Why you may feel depressed and anxious when you're ill and how to cope with it - The Conversation - January 17th, 2024
- New mechanism with potential to boost checkpoint-blocking cancer immunotherapies identified - Medical Xpress - January 17th, 2024
- Battling Bugs and Blues: The Interplay of Infection and Emotion - News-Medical.Net - January 17th, 2024